Department of Biological Sciences and Border Biomedical Research Center, the University of Texas at El Paso, El Paso, Texas, United States of America.
PLoS One. 2013 Sep 9;8(9):e73508. doi: 10.1371/journal.pone.0073508. eCollection 2013.
Green barley extract (GB) was investigated for possible anti-cancer activity by examining its anti-proliferative and pro-apoptotic properties on human leukemia/lymphoma cell lines. Our results indicate that GB exhibits selective anti-proliferative activity on a panel of leukemia/lymphoma cells in comparison to non-cancerous cells. Specifically, GB disrupted the cell-cycle progression within BJAB cells, as manifested by G2/M phase arrest and DNA fragmentation, and induced apoptosis, as evidenced by phosphatidylserine (PS) translocation to the outer cytoplasmic membrane in two B-lineage leukemia/lymphoma cell lines. The pro-apoptotic effect of GB was found to be independent of mitochondrial depolarization, thus implicating extrinsic cell death pathways to exert its cytotoxicity. Indeed, GB elicited an increase of TNF-α production, caspase-8 and caspase-3 activation, and PARP-1 cleavage within pre-B acute lymphoblastic leukemia Nalm-6 cells. Moreover, caspase-8 and caspase-3 activation and PARP-1 cleavage were strongly inhibited/blocked by the addition of the specific caspase inhibitors Z-VAD-FMK and Ac-DEVD-CHO. Furthermore, intracellular signaling analyses determined that GB treatment enhanced constitutive activation of Lck and Src tyrosine kinases in Nalm-6 cells. Taken together, these findings indicate that GB induced preferential anti-proliferative and pro-apoptotic signals within B-lineage leukemia/lymphoma cells, as determined by the following biochemical hallmarks of apoptosis: PS externalization, enhanced release of TNF-α, caspase-8 and caspase-3 activation, PARP-1 cleavage and DNA fragmentation Our observations reveal that GB has potential as an anti-leukemia/lymphoma agent alone or in combination with standard cancer therapies and thus warrants further evaluation in vivo to support these findings.
大麦嫩苗提取物(GB)通过研究其对人白血病/淋巴瘤细胞系的抗增殖和促凋亡特性,来研究其抗癌活性。我们的结果表明,与非癌细胞相比,GB 对一组白血病/淋巴瘤细胞表现出选择性的抗增殖活性。具体而言,GB 破坏了 BJAB 细胞的细胞周期进程,表现为 G2/M 期阻滞和 DNA 片段化,并诱导了凋亡,这表现在两种 B 细胞系白血病/淋巴瘤细胞系中,磷脂酰丝氨酸(PS)向细胞质外膜的易位。GB 的促凋亡作用被发现与线粒体去极化无关,因此暗示了外在的细胞死亡途径发挥其细胞毒性作用。事实上,GB 在前 B 急性淋巴细胞白血病 Nalm-6 细胞中引起 TNF-α 产生增加、半胱天冬酶-8 和半胱天冬酶-3 激活以及 PARP-1 裂解。此外,添加特异性半胱天冬酶抑制剂 Z-VAD-FMK 和 Ac-DEVD-CHO 强烈抑制/阻断半胱天冬酶-8 和半胱天冬酶-3 激活和 PARP-1 裂解。此外,细胞内信号转导分析确定,GB 处理增强了 Nalm-6 细胞中 Lck 和Src 酪氨酸激酶的组成性激活。综上所述,这些发现表明,GB 在 B 细胞系白血病/淋巴瘤细胞中诱导了优先的抗增殖和促凋亡信号,这可以通过凋亡的以下生化特征来确定:PS 外化、TNF-α、半胱天冬酶-8 和半胱天冬酶-3 激活、PARP-1 裂解和 DNA 片段化。我们的观察结果表明,GB 具有作为单独的抗白血病/淋巴瘤药物或与标准癌症疗法联合使用的潜力,因此需要进一步在体内评估以支持这些发现。